Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause White blood cell count abnormal? 407 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 407 reports of White blood cell count abnormal have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.6% of all adverse event reports for RUXOLITINIB.

407
Reports of White blood cell count abnormal with RUXOLITINIB
0.6%
of all RUXOLITINIB reports
16
Deaths
52
Hospitalizations

How Dangerous Is White blood cell count abnormal From RUXOLITINIB?

Of the 407 reports, 16 (3.9%) resulted in death, 52 (12.8%) required hospitalization, and 4 (1.0%) were considered life-threatening.

Is White blood cell count abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 407 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause White blood cell count abnormal?

IBRUTINIB (459) PALBOCICLIB (429) RITUXIMAB (348) LENALIDOMIDE (347) PEGFILGRASTIM (245) TOCILIZUMAB (242) FENTANYL (234) FLUOXETINE (232) VENETOCLAX (231) BUPROPION (227)

Which RUXOLITINIB Alternatives Have Lower White blood cell count abnormal Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All White blood cell count abnormal Reports All Drugs Causing White blood cell count abnormal RUXOLITINIB Demographics